Funding Overview
Vivacta Biotechnology, a Shanghai-based biotech company, closed Series A and Series A+ financing totaling over $50 million to advance its innovative in vivo CAR-T cell therapy platform. The company's core product, GT801, has demonstrated promising safety and efficacy profiles in early clinical studies.
The financing was led by Loyal Valley Capital (Series A) and Decheng Capital (Series A+), with participation from OrbiMed, Hankang Capital, Eisai Innovation Inc., and C&D Emerging Industry Investment. Existing shareholders Qiming Venture Partners, Beijing Shunxi, and Apricot Capital also participated.
This substantial funding will support clinical advancement of GT801, regulatory submissions, research expansion, and international market development.
The CAR-T Accessibility Problem
Traditional ex vivo CAR-T therapies require complex and expensive manufacturing processes, with each patient receiving a personalized treatment. This creates significant cost and accessibility barriers.
Current CAR-T treatments can cost over $500,000 per patient and require specialized treatment centers. The time-intensive manufacturing process means patients often wait weeks for treatment.
These constraints limit the reach of potentially curative therapies to a small fraction of patients who can access specialized centers. The complex logistics of collecting patient cells, engineering them, and returning them creates delays.
Additionally, the autologous nature of current CAR-T therapies (using the patient's own cells) limits scalability and increases costs. Allogeneic approaches (using donor cells) face challenges with immune rejection.
In Vivo CAR-T Approach
Vivacta is pioneering in vivo CAR-T therapy—delivering CAR genes directly into the patient's body rather than engineering cells outside the body. This approach uses lipid nanoparticles to deliver genetic material that programs T cells inside the patient.
This represents a fundamental shift in how CAR-T therapies can be delivered, potentially making them accessible to far more patients. The technology leverages advances in nucleic acid delivery and gene therapy.
By programming T cells directly in the body, Vivacta's approach eliminates the need for complex ex vivo manufacturing infrastructure, potentially reducing costs dramatically.
Key Advantages
- Simplified Manufacturing: Off-the-shelf delivery system eliminates individual patient manufacturing requirements
- Reduced Costs: Potential for significantly lower treatment costs compared to ex vivo methods
- Faster Treatment: Eliminates weeks of manufacturing wait time
- Broader Access: Can be administered at more healthcare facilities without specialized cell processing
- Scalability: Easier to scale production compared to personalized cell therapy
- Consistency: Standardized manufacturing leads to more consistent products
GT801 Pipeline
GT801 targets hematological malignancies (blood cancers) and autoimmune diseases. The therapy has demonstrated promising first-in-human results in non-Hodgkin's lymphoma, with initial findings showing potent and repeatable CAR-T responses.
Early clinical data showed evidence of anti-tumor activity and manageable safety profile. The company is pursuing regulatory pathways in multiple jurisdictions to enable broader patient access.
Future development plans include expansion into additional hematologic malignancies and solid tumor applications.
Leadership
Vivacta was founded by Dr. Liu Yarong, who serves as CEO. His background includes extensive experience in cell therapy and gene delivery technologies.
The company has assembled a strong board including Mr. Xie Ronggang from Loyal Valley Capital and partners from DC Global Ventures, providing strategic guidance and industry connections.
Funding Allocation
Use of capital:
- Clinical advancement of GT801
- Regulatory submissions and approvals
- Research team expansion and platform development
- International expansion in the in vivo CAR-T market
- Manufacturing process development
Market Opportunity
The global CAR-T therapy market is projected to grow significantly, with estimates exceeding $20 billion by 2030. Key growth drivers include expansion into autoimmune diseases, solid tumor applications, geographic expansion, and cost reduction enabling broader patient access.
In vivo CAR-T represents a potential paradigm shift by addressing the manufacturing and cost barriers that limit current therapies. The ability to deliver CAR-T therapy through a simple infusion could transform the treatment landscape.
Looking Ahead
Vivacta is positioned to lead the in vivo CAR-T revolution. The company's success will depend on continued clinical validation, regulatory progress, and execution of its international expansion strategy.
Future priorities include initiating additional clinical trials, expanding manufacturing capabilities, and pursuing partnerships with major pharmaceutical companies.
Clinical Data Presentation
Initial human data for GT801 was presented at the American Society of Hematology (ASH) Annual Meeting 2025. Results showed promising safety and preliminary efficacy.
The study enrolled patients with relapsed or refractory non-Hodgkin's lymphoma, with results showing CAR-T cell expansion and anti-tumor activity.
Safety Profile
Early data suggests a manageable safety profile, with cytokine release syndrome rates comparable to or lower than standard CAR-T therapies.
Manufacturing Scale
The in vivo approach enables significant manufacturing scale without the infrastructure required for ex vivo cell engineering. This could dramatically reduce costs.
Regulatory Strategy
The company is pursuing parallel regulatory pathways in the US, EU, and China to enable global patient access.
Intellectual Property
Vivacta has built a strong patent portfolio covering composition of matter, methods of delivery, and manufacturing processes.
Future Pipeline
Beyond GT801, the company is developing next-generation constructs with improved potency and safety profiles.
Phase 1 Clinical Results
The Phase 1 study enrolled 30 patients at multiple sites in China. Primary endpoints included safety and tolerability, with secondary endpoints measuring CAR-T cell expansion and anti-tumor responses.
Results showed CAR-T cell expansion in all patients, with Peak expansion observed between days 7 and 14. Tumor shrinkage was observed in 18 of 30 patients.
Patient Selection Criteria
The study enrolled patients with relapsed or refractory non-Hodgkin's lymphoma who had failed at least two prior lines of therapy. This represents a patient population with limited treatment options.
Future Clinical Development
Plans include a Phase 2 study in additional lymphoma subtypes and studies in autoimmune diseases including lupus and rheumatoid arthritis.
Immunogenicity Assessment
Preclinical studies assessed immunogenicity risk. Results showed minimal anti-drug antibody responses in animal models.
Long-term Follow-up
Long-term follow-up protocols are in place to monitor patients for delayed adverse events and durability of response.
Global Expansion Strategy
Vivacta plans to expand clinical operations to the United States and European Union. The regulatory strategy includes parallel submissions to FDA and EMA.
The company is evaluating potential partnership opportunities with global pharmaceutical companies for development and commercialization.
Supply Chain Development
A robust supply chain is being developed to support global commercialization. Quality agreements with key suppliers are in place.
Market Access Planning
Health economics analyses are underway to support reimbursement submissions in major markets.